Published in J Biol Chem on October 12, 2015
Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid (2016) 0.76
Distinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity. PLoS One (2016) 0.76
Solid-State NMR Studies Reveal Native-like β-Sheet Structures in Transthyretin Amyloid. Biochemistry (2016) 0.75
Multisite aggregation of p53 and implications for drug rescue. Proc Natl Acad Sci U S A (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr (2011) 67.55
Structure of the cross-beta spine of amyloid-like fibrils. Nature (2005) 11.56
Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr (2004) 10.96
Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature (2007) 10.02
Automated structure solution with the PHENIX suite. Methods Mol Biol (2008) 5.65
The amyloid state of proteins in human diseases. Cell (2012) 4.53
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med (1997) 3.65
Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A (2010) 3.50
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry (1996) 3.42
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry (1992) 3.19
The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A (2006) 2.88
Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A (1990) 2.87
Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature (2011) 2.46
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med (1983) 2.13
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry (2001) 1.85
Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A (2011) 1.76
Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem (2001) 1.70
The common architecture of cross-beta amyloid. J Mol Biol (2009) 1.69
Amyloidosis. Crit Rev Clin Lab Sci (1994) 1.63
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet (2000) 1.54
Structural models of amyloid-like fibrils. Adv Protein Chem (2006) 1.49
The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci U S A (2001) 1.45
Arrangement of subunits and ordering of beta-strands in an amyloid sheet. Nat Struct Biol (2002) 1.43
The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry (2005) 1.32
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol (2005) 1.21
Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Acc Chem Res (2008) 1.19
Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP? J Mol Biol (2005) 1.19
Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife (2013) 1.11
Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol (2008) 1.08
Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis. Amyloid (2001) 0.99
Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail (2012) 0.99
Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab (1993) 0.93
Conformational change and assembly through edge beta strands in transthyretin and other amyloid proteins. Acc Chem Res (2006) 0.93
Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid (1998) 0.93
Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc Natl Acad Sci U S A (2013) 0.92
Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther (2014) 0.92
Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys Chem (2000) 0.92
Localized structural fluctuations promote amyloidogenic conformations in transthyretin. J Mol Biol (2013) 0.88
Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation. J Biol Chem (2012) 0.85
Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. Lab Invest (2013) 0.83
Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. J Clin Endocrinol Metab (1989) 0.83
Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. J Pept Res (2004) 0.83
Effect of proline mutations on the monomer conformations of amylin. Biophys J (2013) 0.83
An in vitro selection strategy for conferring protease resistance to ligand binding peptides. Protein Eng Des Sel (2009) 0.83
Destabilization of transthyretin by pathogenic mutations in the DE loop. Proteins (2007) 0.80
Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils. PLoS One (2012) 0.78